Soligenix receives agreement from fda on initial pediatric study plan for hybryte™ for the treatment of cutaneous t-cell lymphoma

Princeton, n.j. , july 27, 2022 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received agreement from the us food & drug administration (fda) on an initial pediatric study plan (ipsp) for hybryte™ (synthetic hypericin) for the treatment of cutaneous t-cell lymphoma (ctcl).
SNGX Ratings Summary
SNGX Quant Ranking